Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit from First-Line Rituximab in Follicular Lymphoma.
EJHAEM（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined